Major Customers and Segment Information (Tables)

9 Months Ended

Jun. 30, 2013

Segment Reporting [Abstract]

Segment Information

Segment information for the interim periods is as follows:

	U.S. Diagnostics		European Diagnostics		Life Science		Eliminations(1)			Total
Three Months Ended June 30, 2013
Net sales—
Third-party	$	29,535	$	5,770	$	11,803	$	—		$	47,108
Inter-segment		2,771		3		356		(3,130	)		—
Operating income		11,876		439		3,543		(159	)		15,699
Goodwill (June 30, 2013)		1,250		—		21,137		—			22,387
Other intangible assets, net (June 30, 2013)		1,716		—		6,593		—			8,309
Total assets (June 30, 2013)		94,566		12,869		105,942		(42,386	)		170,991
Three Months Ended June 30, 2012
Net sales—
Third-party	$	26,008	$	5,897	$	10,010	$	—		$	41,915
Inter-segment		2,464		5		133		(2,602	)		—
Operating income (2)		9,442		998		2,118		54			12,612
Goodwill (September 30, 2012)		1,250		—		21,896		—			23,146
Other intangible assets, net (September 30, 2012)		2,239		—		8,025		—			10,264
Total assets (September 30, 2012)		82,654		15,443		101,706		(38,422	)		161,381
Nine Months Ended June 30, 2013
Net sales—
Third-party	$	90,211	$	17,166	$	32,347	$	—		$	139,724
Inter-segment		7,353		9		864		(8,226	)		—
Operating income		34,731		1,169		8,223		(80	)		44,043
Nine Months Ended June 30, 2012
Net sales—
Third-party	$	79,472	$	18,326	$	31,431	$	—		$	129,229
Inter-segment		7,428		9		793		(8,230	)		—
Operating income (2)		29,377		2,398		5,526		(57	)		37,244

(1) Eliminations consist of inter-segment transactions.

(2) Life Science includes $366 and $1,013 of costs related to consolidation of the Maine operations into the Tennessee facility during the three and nine months ended June 30, 2012, respectively.